EP1028735A4 - Methode therapeutiques comportant l'utilisation d'une neureguline - Google Patents

Methode therapeutiques comportant l'utilisation d'une neureguline

Info

Publication number
EP1028735A4
EP1028735A4 EP98949803A EP98949803A EP1028735A4 EP 1028735 A4 EP1028735 A4 EP 1028735A4 EP 98949803 A EP98949803 A EP 98949803A EP 98949803 A EP98949803 A EP 98949803A EP 1028735 A4 EP1028735 A4 EP 1028735A4
Authority
EP
European Patent Office
Prior art keywords
neuregulin
therapeutic methods
therapeutic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98949803A
Other languages
German (de)
English (en)
Other versions
EP1028735A1 (fr
Inventor
Robert N Mcburney
William Holt
David I Gwynne
Mark Marchionni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenes Pharmaceuticals Inc
Original Assignee
Cenes Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenes Pharmaceuticals Inc filed Critical Cenes Pharmaceuticals Inc
Publication of EP1028735A1 publication Critical patent/EP1028735A1/fr
Publication of EP1028735A4 publication Critical patent/EP1028735A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP98949803A 1997-10-14 1998-10-08 Methode therapeutiques comportant l'utilisation d'une neureguline Withdrawn EP1028735A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6210997P 1997-10-14 1997-10-14
US62109P 1997-10-14
PCT/US1998/021349 WO1999018976A1 (fr) 1997-10-14 1998-10-08 Methode therapeutiques comportant l'utilisation d'une neureguline

Publications (2)

Publication Number Publication Date
EP1028735A1 EP1028735A1 (fr) 2000-08-23
EP1028735A4 true EP1028735A4 (fr) 2003-08-06

Family

ID=22040281

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98949803A Withdrawn EP1028735A4 (fr) 1997-10-14 1998-10-08 Methode therapeutiques comportant l'utilisation d'une neureguline

Country Status (6)

Country Link
EP (1) EP1028735A4 (fr)
JP (1) JP2001519400A (fr)
KR (1) KR20010031103A (fr)
AU (1) AU745324B2 (fr)
CA (1) CA2306228A1 (fr)
WO (1) WO1999018976A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
WO2001058948A2 (fr) * 2000-02-11 2001-08-16 Proteosys Ag UTILISATION DE NEUREGULINE-β EN TANT QU'INDICATEUR ET/OU CIBLE
DE10006175A1 (de) * 2000-02-11 2001-08-23 Andre Schrattenholz Verwendung von Neuregulin-beta
EP1417230A2 (fr) 2001-08-06 2004-05-12 ProteoSys AG Isoformes de neureguline-beta associes a des processus neuronaux
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2003101401A2 (fr) 2002-06-03 2003-12-11 Chiron Corporation Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
WO2006097463A2 (fr) * 2005-03-15 2006-09-21 Ares Trading S.A. Compositions et methodes destinees a traiter des troubles inflammatoires
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) * 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
WO2009062750A2 (fr) 2007-11-16 2009-05-22 Proteosys Ag Isoformes solubles actives de neuréguline modifiées de façon post-traductionnelle
EP2276502A4 (fr) * 2008-05-23 2012-04-04 Morehouse School Of Medicine Compositions pour la prévention et le traitement de lésions neurologiques et méthodes d'utilisation associées
EP2328606B1 (fr) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Compositions et procédés de traitement durant des périodes non aiguës consécutives à une lésion neurologique du système nerveux central
WO2010084150A1 (fr) 2009-01-23 2010-07-29 Proteosys Ag Procédé de diagnostic pour détecter des maladies neurodégénératives
CA2708674C (fr) * 2009-05-22 2018-05-15 Morehouse School Of Medicine Compositions renfermant de la neureguline pour la prevention et le traitement de blessure neurologique et methodes d'utilisation connexes
KR101186218B1 (ko) * 2009-08-21 2012-10-08 경희대학교 산학협력단 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드의 용도
CA2845198A1 (fr) * 2010-08-13 2012-02-16 Georgetown University Ggf2 et procedes d'utilisation
WO2013053076A1 (fr) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions et procédés pour le traitement de l'insuffisance cardiaque
JP2013135660A (ja) * 2011-11-28 2013-07-11 Nara Institute Of Science & Technology ニューレグリン−１（Ｎｅｕｒｅｇｕｌｉｎ−１）部分ペプチド
CN104321072A (zh) * 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
EP2999499B1 (fr) 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Libération prolongée de neuréguline pour le traitement de l'insuffisance cardiaque
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
WO2017182500A1 (fr) * 2016-04-19 2017-10-26 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Neuréguline destinée au traitement et/ou à la prévention de tumeurs du système nerveux
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US20230057622A1 (en) 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015812A1 (fr) * 1994-11-17 1996-05-30 Cambridge Neuroscience, Inc. Utilisation de neuregulines comme modulateurs de la communication cellulaire
WO1996030403A1 (fr) * 1995-03-27 1996-10-03 Cambridge Neuroscience, Inc. Procedes de traitement de troubles oculaires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
DE59307910D1 (de) * 1992-03-05 1998-02-12 Ciba Geigy Ag Reaktivfarbstoffe, Verfahren zu deren Herstellung und deren Verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015812A1 (fr) * 1994-11-17 1996-05-30 Cambridge Neuroscience, Inc. Utilisation de neuregulines comme modulateurs de la communication cellulaire
WO1996030403A1 (fr) * 1995-03-27 1996-10-03 Cambridge Neuroscience, Inc. Procedes de traitement de troubles oculaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCHIONNI M.A. ET AL.: "Neuregulins as potential drugs for neurological disorders.", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY., vol. 61, 1996, pages 459 - 472, XP009007573 *
See also references of WO9918976A1 *

Also Published As

Publication number Publication date
AU9604298A (en) 1999-05-03
JP2001519400A (ja) 2001-10-23
AU745324B2 (en) 2002-03-21
KR20010031103A (ko) 2001-04-16
WO1999018976A1 (fr) 1999-04-22
EP1028735A1 (fr) 2000-08-23
CA2306228A1 (fr) 1999-04-22

Similar Documents

Publication Publication Date Title
SI0979269T1 (en) Use of a fermenter
GB9523583D0 (en) Therapeutic agents
HU9700071D0 (en) Use of muramilpeptides
GB9719161D0 (en) New therapeutic method
GB9620777D0 (en) Therapeutic use
IL130209A (en) Therapeutic application of a thienylcylohexylamine derivatives
GB9723999D0 (en) Therapeutic use
GB9726701D0 (en) Therapeutic use
GB2294532B (en) Use of a Crucible
GB9726702D0 (en) Therapeutic use
TW328219U (en) Structure of a chair-ladder
GB9719176D0 (en) New therapeutic method
GB9721171D0 (en) Therapeutic use
GB9721221D0 (en) Therapeutic use
GB9717260D0 (en) Therapeutic use
GB9721190D0 (en) Therapeutic use
GB9721192D0 (en) Therapeutic use
GB9721173D0 (en) Therapeutic use
GB9726699D0 (en) Therapeutic use
GB9721220D0 (en) Therapeutic use
GB9721195D0 (en) Therapeutic use
GB9721194D0 (en) Therapeutic use
GB9721179D0 (en) Therapeutic use
GB9708289D0 (en) Therapeutic use
GB9726700D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000504

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENES PHARMACEUTICALS INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENES PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 48/00 B

Ipc: 7C 07K 14/475 B

Ipc: 7A 61K 38/18 A

Ipc: 7A 61P 25/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050503